DLL3 and benign neoplasm of prostate: A recent study showed that the NOTCH ligand delta-like 3 (DLL3) is expressed in >76% of neuroendocrine prostate cancers, while it is expressed in only a small subset of castration-resistant prostate adenocarcinomas and virtually not expressed in localized prostate cancers and in benign prostate tumors [679].